Összefoglaló. Az agy és a szem vascularis katasztrófái számos esetben egymáshoz társuló vagy egymást előre jelző kórképek. Az arteria centralis retinae occlusio az ér rekanalizációjának hiányában a retina szöveteinek irreverzibilis károsodását okozza. Sem a nemzetközi, sem a hazai stroke-irányelvek nem foglalkoznak az ocularis stroke problémakörével, annak ellenére, hogy az arteria centralis retinae occlusio okozta retinalis ischaemia minden tekintetben megfelel az akut ischaemiás stroke definíciójának. Az eddig rendelkezésre álló irodalmi adatok alapján arteria centralis retinae occlusio esetén az intravénás thrombolysis 4,5 órán belül alkalmazva növeli a szignifikáns mértékű visusjavulás esélyét. Az országban jelenleg 4 centrum (Pécsi Tudományegyetem, Szegedi Tudományegyetem, Debreceni Egyetem, Semmelweis Egyetem) tervezi az ocularis stroke kezelésében a thrombolysis bevezetését. A maradandó látásromlás és a szekunder cerebrovascularis események megelőzése érdekében elengedhetetlen az alapellátásban és a társszakmákban dolgozó kollégákkal való szoros együttműködés. Orv Hetil. 2021; 162(47): 1871–1875.
Summary. Vascular events of the brain and the eye may occur concomitantly or sequentially. In the absence of recanalization, central retinal artery occlusion causes irreversible damage to the retinal tissues. Even though retinal ischemia secondary to central retinal artery occlusion meets the definition of acute ischemic stroke, neither the international nor the Hungarian stroke guidelines mention ocular stroke. Based on the available literature, intravenous thrombolysis of the central retinal artery within 4.5 hours of occlusion can increase the odds of significant vision improvement. Currently 4 centers (University of Pécs, Debrecen, Szeged, and Semmelweis University) are planning to introduce thrombolysis in the treatment of ocular stroke. To prevent permanent visual loss and secondary cerebrovascular events, timely intervention requires the collaboration between general practitioners and other specialties. Orv Hetil. 2021; 162(47): 1871–1875.
Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 2064–2089.
Schrag M, Youn T, Schindler J, et al. Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient-level meta-analysis. JAMA Neurol. 2015; 72: 1148–1154.
Leavitt JA, Larson TA, Hodge DO, et al. The incidence of central retinal artery occlusion in Olmsted County, Minnesota. Am J Ophthalmol. 2011; 152: 820–823.e2.
Monro TK. Optic nerve as part of the central nervous system. J Anat Physiol. 1895; 30(Pt 1): 45–48.
Hayreh SS, Zimmerman MB, Kimura A, et al. Central retinal artery occlusion. Retinal survival time. Exp Eye Res. 2004; 78: 723–736.
Tobalem S, Schutz JS, Chronopoulos A. Central retinal artery occlusion – rethinking retinal survival time. BMC Ophthalmol. 2018; 18: 101.
Arruga J, Sanders MD. Ophthalmologic findings in 70 patients with evidence of retinal embolism. Ophthalmology 1982; 89: 1336–1347.
Cho KH, Ahn SJ, Cho JH, et al. The characteristics of retinal emboli and its association with vascular reperfusion in retinal artery occlusion. Invest Ophthalmol Vis Sci. 2016; 57: 4589–4598.
Varma D, Cugati S, Lee A, et al. A review of central retinal artery occlusion: clinical presentation and management. Eye (Lond). 2013; 27: 688–697.
Mac Grory B, Schrag M, Biousse V, et al. Management of central retinal artery occlusion: a scientific statement from the American Heart Association. Stroke 2021; 52: e282–e294. [Erratum: Stroke 2021; 52: e309.]
Mehta N, Marco RD, Goldhardt R, et al. Central retinal artery occlusion: acute management and treatment. Curr Ophthalmol Rep. 2017; 5: 149–159.
Schumacher M, Schmidt D, Jurklies B, et al. Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. Ophthalmology 2010; 117: 1367–1375.e1.
Chen CS, Lee AW, Campbell B, et al. Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: report from a randomized, controlled trial. Stroke 2011; 42: 2229–2234.
Préterre C, Godeneche G, Vandamme X, et al. Management of acute central retinal artery occlusion: intravenous thrombolysis is feasible and safe. Int J Stroke 2017; 12: 720–723.
Nedelmann M, Graef M, Weinand F, et al. Retrobulbar spot sign predicts thrombolytic treatment effects and etiology in central retinal artery occlusion. Stroke 2015; 46: 2322–2324.
Schultheiss M, Härtig F, Spitzer MS, et al. Intravenous thrombolysis in acute central retinal artery occlusion – a prospective interventional case series. PLoS ONE 2018; 13: e0198114.
Mac Grory B, Nackenoff A, Poli S, et al. Intravenous fibrinolysis for central retinal artery occlusion: a cohort study and updated patient-level meta-analysis. Stroke 2020; 51: 2018–2025.
Youn TS, Lavin P, Patrylo M, et al. Current treatment of central retinal artery occlusion: a national survey. J Neurol. 2018; 265: 330–335. [Epub 2017 Dec 13]